title: Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.
abstract: Bevacizumab is an antiangiogenic agent approved for recurrent glioblastoma due to high response rates. Prior reviews focused on severe or cardiovascular bevacizumab toxicities. We performed a comprehensive review of toxicities experienced among 210 patients enrolled in 3 phase II bevacizumab trials for recurrent malignant gliomas at the National Cancer Institute. No bevacizumab toxicities were experienced by 20 % patients, 40.2 % on monotherapy versus ≤9.5 % on combination therapy. Hypertension and proteinuria occurred in ~25 %. Fatigue, hypophosphatemia, aspartate aminotransferase elevation, rashes were common. Low grade headache, hoarseness, myalgias/arthralgias, liver enzyme elevation, azotemia and electrolyte abnormalities were noted. Rare severe toxicities, including thrombosis, hemorrhage, wound complications and colonic perforations, occurred at rates seen in other diseases. Leukopenia and neutropenia occurred solely with combination therapy, while thrombocytopenia occurred in 12.5 % on bevacizumab monotherapy. Thrombocytopenia was generally mild, but severe in (1.4 %) and increased in frequency with prolonged or combination therapy. Bevacizumab-related deaths occurred in 4 (1.9 %) patients, including brain ischemia (n = 1) and sudden unexplained deaths (n = 2). Prior hypertension increased the odds of hypertension by ≥3.4-fold (p < 0.001) and grade 3+ hypertension by ≥11.2 (p < 0.001). Prior hypertension increased the odds of hypophosphatemia by 2.4-fold (p = 0.011), but failed to predict proteinuria or azotemia. Age did not greatly impact toxicity. Hypertension, proteinuria and hypophosphatemia often occurred concurrently, more frequently and severely with prolonged use. Our study shows bevacizumab monotherapy is well tolerated, but toxicity increases with combination therapy. Balancing the risks and benefits of bevacizumab requires understanding the spectrum of bevacizumab toxicities and predisposing factors.
authors.affiliation: Division of Neuro-Oncology, Neurologic Institute of New York, Columbia University College of Physicians and Surgeons, 710 West 168th Street, NI 9-017, New York, NY, 10032, USA, yo2240@cumc.columbia.edu.
authors.forename: Yazmin
authors.initials: Y
authors.lastname: Odia
authors.forename: Joanna H
authors.initials: JH
authors.lastname: Shih
authors.forename: Teri N
authors.initials: TN
authors.lastname: Kreisl
authors.forename: Howard A
authors.initials: HA
authors.lastname: Fine
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D017322:Clinical Trials, Phase II as Topic; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000473:pathology; D017674:Hypophosphatemia / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D054547:National Cancer Institute (U.S.); D060787:Neoplasm Grading; D011379:Prognosis; D011507:Proteinuria / Q000139:chemically induced* / Q000473:pathology; D015996:Survival Rate; D014481:United States; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
references.citation: Lancet. 2007 Dec 22;370(9605):2103-11
references.pmid: 18156031
references.citation: Lancet Oncol. 2005 May;6(5):266
references.pmid: 15889502
references.citation: J Neurooncol. 2011 Jan;101(1):155-9
references.pmid: 20524043
references.citation: Acta Neuropathol. 2007 Aug;114(2):97-109
references.pmid: 17618441
references.citation: Nature. 1994 Feb 10;367(6463):576-9
references.pmid: 8107827
references.citation: Oncologist. 2008 Oct;13(10):1084-96
references.pmid: 18838439
references.citation: J Clin Oncol. 2009 Feb 10;27(5):740-5
references.pmid: 19114704
references.citation: Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
references.pmid: 23095881
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1148-54
references.pmid: 19857784
references.citation: Ann Pharmacother. 2009 Mar;43(3):490-501
references.pmid: 19261963
references.citation: Neuro Oncol. 2008 Dec;10(6):1025-34
references.pmid: 18667747
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1253-9
references.pmid: 17317837
references.citation: J Clin Oncol. 1999 Aug;17(8):2572-8
references.pmid: 10561324
references.citation: Expert Rev Anticancer Ther. 2009 Jun;9(6):795-805
references.pmid: 19496716
references.citation: Oncologist. 2010;15(2):130-41
references.pmid: 20139170
references.citation: Oncologist. 2010;15(7):683-94
references.pmid: 20547589
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references.pmid: 17947719
references.citation: Adv Ther. 2011 Apr;28(4):334-40
references.pmid: 21432029
references.citation: J Neurosurg. 1958 Sep;15(5):489-503
references.pmid: 13576192
references.citation: Oncology. 2012;82(4):218-27
references.pmid: 22508241
references.citation: Radiother Oncol. 2002 Sep;64(3):259-73
references.pmid: 12242114
references.citation: Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5
references.pmid: 9422557
references.citation: N Engl J Med. 2014 Feb 20;370(8):699-708
references.pmid: 24552317
references.citation: PLoS One. 2012;7(6):e38364
references.pmid: 22719881
references.citation: Best Pract Res Clin Haematol. 2009 Mar;22(1):115-28
references.pmid: 19285278
references.citation: Nat Rev Clin Oncol. 2009 Aug;6(8):465-77
references.pmid: 19581909
references.citation: J Child Neurol. 2012 Jul;27(7):927-9
references.pmid: 22190499
references.citation: J Clin Oncol. 2010 Jun 20;28(18):3069-75
references.pmid: 20479404
references.citation: J Neurooncol. 2001 Nov;55(2):91-100
references.pmid: 11817706
references.citation: Clin Lung Cancer. 2009 Jan;10(1):28-35
references.pmid: 19289369
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3706-12
references.pmid: 15867200
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: Neuro Oncol. 2011 Oct;13(10):1143-50
references.pmid: 21865400
references.citation: PLoS One. 2013;8(1):e51780
references.pmid: 23349675
references.citation: Nature. 1992 Oct 29;359(6398):845-8
references.pmid: 1279432
references.citation: Cancer Res. 1991 Feb 15;51(4):1345-51
references.pmid: 1705174
references.citation: J Thorac Oncol. 2012 Jan;7(1):203-11
references.pmid: 22173662
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55
references.pmid: 16111571
references.citation: N Engl J Med. 2014 Feb 20;370(8):709-22
references.pmid: 24552318
references.citation: J Neurooncol. 2011 Nov;105(2):281-9
references.pmid: 21603965